07.12.2010 • News • Merck • Millipore • Mergers & Acquisitions (M&A)

Uta Kemmerich-Keil: Merck KGaA to Refrain From Big Deals For Now

Uta Kemmerich-Keil is the head of Mercks corporate finance — Uta Kemmerich-Keil is the head of Merck's corporate finance

German drugmaker Merck KGaA will take a breather from pursuing larger takeover deals as it integrates its latest acquisition Millipore, a company executive said on Tuesday.

"You will not see us involved in transactions of (Millipore's) size in the short term," the company's head of corporate finance, Uta Kemmerich-Keil, said at an event, adding that management's focus was on integrating the laboratory equipment supplier.

Merck agreed to buy U.S. biotech tool maker Millipore for $6 billion in cash in February to diversify away from its pharmaceuticals business.

Company

Merck KGaA

Frankfurter Str. 250
64293 Darmstadt
Germany

Company contact

I am interested in:

an offer
a callback
detailed information

Your request

salutation first name last name

country phone email

Please note our data protection information for the contact form.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.